Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment.
Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment.
Clin J Oncol Nurs. 2018 Oct 01;22(5):542-548
Authors: Edwards RL, Andan C, Lalla RV, Lacouture ME, O'Brien D, Sequist LV
Abstract
BACKGROUND: Afatinib is an oral, irreversible ErbB family blocker indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with non-resistant epidermal growth factor receptor (EGFR) mutations. Afatinib is also approved for the treatment of metastatic squamous NSCLC following progression on platinum-based chemotherapy. Common afatinib-associated toxicities include gastrointestinal and dermatologic events, which can be dose limiting.
OBJECTIVES: In this review, the authors describe clinical trial experiences with afatinib, as well as best practices and practical approaches to the management of afatinib-associated adverse events in EGFR mutation-positive NSCLC.
METHODS: Safety and tolerability data from phase 3 trials of afatinib were reviewed, together with real-life experiences from the authors' clinical practices.
FINDINGS: Patient education, combined with early assessment and effective management of afatinib-related adverse events as well as dose- reduction strategies, allows patients to continue treatment and maximize the clinical benefits of afatinib.
PMID: 30239509 [PubMed - in process]
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Edwards RL, Andan C, Lalla RV, Lacouture ME, O'Brien D, Sequist LV Tags: Clin J Oncol Nurs Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Dermatology | Education | Gastroenterology | Lung Cancer | Non-Small Cell Lung Cancer | Nurses | Nursing | Oral Cancer | Skin | Toxicology | Universities & Medical Training